Yahoo Finance·2026-02-13 19:22Core Insights - CRISPR Therapeutics reported $864,000 in fourth-quarter revenue, resulting in a loss of $1.37 per share, which was worse than analysts' expectations of a loss of $1.20 per share on higher sales [1] - Despite the disappointing earnings report, CRISPR shares rose by 9.7%, largely due to positive developments from its commercialization partner, Vertex Pharmaceuticals [1] Group 1: Company Performance - CRISPR Therapeutics' gene-editing therapy, Casgevy, is the first FDA-approved gene-editing therapy for sickle cell disease, but the company faces significant losses and unpredictable revenue typical of young biotech firms [2] - Vertex Pharmaceuticals, the licensee for Casgevy, reported $54 million in revenue from the therapy in the fourth quarter and anticipates $500 million or more in revenue from non-cystic fibrosis products, including increased patient infusions of Casgevy by 2026 [3] Group 2: Market Outlook - Vertex's guidance for Casgevy's sales growth in 2026 indicates expectations for substantial revenue growth beyond the $116 million total revenue projected for 2025 [4] - The commercialization of Casgevy is expected to take time, as treatment centers require preparation and patient-specific treatments take additional months to create, with the therapy costing over $2 million per patient [5]